- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
Patent holdings for IPC class A61K 31/573
Total number of patents in this class: 4254
10-year publication summary
|
347
|
394
|
411
|
438
|
437
|
457
|
455
|
462
|
380
|
196
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Chiesi Farmaceutici S.p.A. | 968 |
60 |
| Janssen Biotech, Inc. | 1552 |
50 |
| Genentech, Inc. | 3971 |
43 |
| The Regents of the University of California | 19898 |
40 |
| Celgene Corporation | 1400 |
34 |
| Sage Therapeutics, Inc. | 365 |
29 |
| Janssen Pharmaceutica N.V. | 3395 |
28 |
| Allergan, Inc. | 2349 |
24 |
| The Board of Trustees of the Leland Stanford Junior University | 6402 |
24 |
| Regeneron Pharmaceuticals, Inc. | 4255 |
24 |
| AVM Biotechnology, LLC | 26 |
22 |
| Mexichem Fluor, Sociedad Anonima de Capital Variable | 203 |
21 |
| Antecip Bioventures II LLC | 329 |
20 |
| Chugai Seiyaku Kabushiki Kaisha | 1354 |
20 |
| ReveraGen Biopharma, Inc. | 32 |
20 |
| Oculis Operations Sàrl | 35 |
20 |
| Bristol-myers Squibb Company | 4878 |
19 |
| Massachusetts Institute of Technology | 10051 |
19 |
| Board of Regents, The University of Texas System | 5786 |
18 |
| Cassiopea S.P.A. | 49 |
18 |
| Other owners | 3701 |